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Abstract
Background: A small proportion of non–small cell lung cancers (NSCLCs) have been observed to spread to distant lymph
nodes (N3) or metastasize (M1) or both, while the primary tumor is small (3 cm, T1). These small aggressive NSCLCs (SA-
NSLSC) are important as they are clinically significant, may identify unique biologic pathways, and warrant aggressive
follow-up and treatment. This study identifies factors associated with SA-NSCLC and attempts to validate a previous finding
that women with a family history of lung cancer are at particularly elevated risk of SA-NSCLC.
Methods: This study used a case–case design within the National Cancer Institute’s National Lung Screening Trial (NLST)
cohort. Case patients and “control” patients were selected based on TNM staging parameters. Case patients (n¼64) had
T1 NSCLCs that were N3 or M1 or both, while “control” patients (n¼206) had T2 or T3, N0 to N2, and M0 NSCLCs. Univariate
and multivariable logistic regression were used to identify factors associated with SA-NSCLC.
Results: In bootstrap bias–corrected multivariable logistic regression models, small aggressive adenocarcinomas were associ-
ated with a positive history of emphysema (odds ratio [OR] ¼ 5.15, 95% confidence interval [CI] ¼ 1.63 to 23.00) and the interac-
tion of female sex and a positive family history of lung cancer (OR¼6.55, 95% CI¼1.06 to 50.80).
Conclusions: Emphysema may play a role in early lung cancer progression. Females with a family history of lung cancer are
at increased risk of having small aggressive lung adenocarcinomas. These results validate previous findings and encourage
research on the role of female hormones interacting with family history and genetic factors in lung carcinogenesis and
progression.
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Article
Researchers from the Prostate, Lung, Colorectal, and Ovarian
Cancer Screening Trial (PLCO) studied a small proportion of
non–small cell lung cancers (NSCLCs) that were found to have
spread to distant lymph nodes or metastasized, or both, while
the primary tumor was relatively small in size (1). These cancers
that were highly aggressive while the primary tumor remained
relatively small were termed small aggressive non–small cell
lung cancers (SA-NSLSCs). Due to their aggressive nature, these
SA-NSCLCs carry a grave prognosis, as they are no longer surgi-
cally resectable with curative intent. It is hypothesized that
these SA-NSCLCs may involve unique biological pathways. In
the previous study, “small” cancers were considered T1 (<3 cm
with minimal invasion of surrounding tissues) (1). Previous
studies reported that as many as 10% of small (3 cm) lung can-
cers were advanced stage at diagnosis (stage IIIB/IV), that is,
with involvement of distant lymph nodes (N3) and/or metasta-
ses (M1) (2–4). Overall, few studies have described or validated
factors associated with SA-NSCLC.
The PLCO-based study by Tammem€agi and colleagues found
that factors associated with SA-NSCLC included age at diagno-
sis, ibuprofen use, sex, and sex by family history of lung cancer
interaction (1). Comparing those diagnosed at age 65 years or
older with those younger than age 65 years, the odds ratio (OR)
for SA-NSCLC was 0.44 (95% confidence interval [CI] ¼ 0.22 to
0.88) (1). The odds ratios for comparing women vs men with SA-
NSCLC in those with and without a family history of lung cancer
were 11.76 (95% CI ¼ 2.00 to 69.22) and 1.86 (95% CI ¼ 0.88 to
3.96), respectively. The sex by family history interaction was
statistically significant (P ¼ .02). Ibuprofen use was found to be
inversely associated with SA-NSCLC (OR ¼ 0.29, 95% CI ¼ 0.11 to
0.76) (1). Ibuprofen use has been thought to be associated with
reduced risk of lung cancer in general (5–10). Other risk factors
identified as having a possible association in univariate model-
ing included smoking duration, history of heart disease/infarc-
tion, and histology (adenocarcinoma vs other NSCLC) (1). In the
PLCO study, 10.4% of SA-NSCLCs occurred in never smokers (1).
Validation of some of these findings may provide insight into
lung carcinogenesis; in particular, validation of the sex-family
history of lung cancer interaction may stimulate further re-
search into developing an understanding of female hormone-
gene interactions (1).
Overall, research on characterizing and identifying factors
associated with aggressive forms of lung cancer is limited. Our
first study aim was to carry out prespecified hypothesis testing
to validate the previously observed associations between age at
diagnosis and sex-family history of lung cancer interaction and
the outcome of SA-NSCLC. Our second study aim was explor-
atory and attempted to identify associations between novel pre-
dictors and SA-NSCLC. Generally, small cell lung cancers
(SCLCs) metastasize early, and therefore most are considered
small aggressive lung cancers, while this is not generally true
for NSCLC; therefore, NSLSCs are the focus of the current study.
Methods
Study Setting
This study used a case–case design nested within the National
Cancer Institute’s (NCI’s) National Lung Screening Trial (NLST)
cohort. The details of the NLST have been described elsewhere
(11). In brief, the NLST was a randomized controlled screening
trial that compared low-dose computed tomography (LDCT)
with chest radiography (CXR) for screening of high-risk current
and former smokers for lung cancer among 53 452 participants,
enrolled during 2002–2004. On enrollment into NLST, informed
consent was obtained from each participant. Institutional re-
view board (IRB) approval was obtained at each participating
site and the NCI. Eligibility criteria for enrolling high-risk indi-
viduals included age 55 to 74 years, 30 or more pack-years’
smoking history, and smoking cessation of 15 or fewer years for
former smokers. Three rounds of annual screening were sched-
uled. Upon enrollment, all participants completed a question-
naire querying information on demographics, exposures,
medical history, and smoking behaviors. For those diagnosed
with lung cancer, pathology and tumor-staging reports, records
of operative procedures, and initial treatments were abstracted
from medical records. Histology and disease stage were coded
according to the International Classification of Diseases, third
edition (ICD-O3) (12), and the Cancer Staging Manual of the
American Joint Committee on Cancer (AJCC), sixth edition (13),
respectively. When the NLST was conducted, bronchioloalveo-
lar carcinoma (BAC) was the accepted terminology assigned by
pathologists, so we use it here. However, it should be noted that
BACs are now referred to as adenocarcinoma with lepidic fea-
tures. All NSCLCs occurring during the NLST follow-up (2002–
2009) were eligible for study inclusion.
Study Design
The focus of this study was to identify factors associated with
progression to aggressive spread while the primary tumor was
still relatively small. SA-NSCLCs were considered case positive
(caseþ), while large, less aggressive NSCLCs (referred to as
“controls”) were considered case negative (case). SA-NSCLCs
were defined as patients with T1 tumors that had spread to dis-
tant regional lymph nodes (N3), or metastasized (M1), or both.
Controls (case) were defined as tumors that had grown beyond
T1, and excluded individuals with locally aggressive disease
(T4), distant nodal disease (N3), or metastases (M1), resulting in
a control group of patients with tumors that were T2 to T3, N0
to N2, and M0. Henceforth, the case- group is referred to as the
control group. Tumor sizes were categorized (30 mm vs> 30
mm) using pathology data, and in the absence of pathology
data, clinical data were used. Large, aggressive (T2-T4/N3/M1,
n ¼ 161) and small, nonaggressive lung cancers (T1/N0-N2/M0,
n ¼ 641) are excluded from the study sample because their
aggressive status at the time of transition from small to large
was unknown.
Statistical Analysis
Categorical variables were assessed using contingency table
analyses, and differences in distributions were evaluated using
Fisher exact tests. For continuous variables, with approximately
normal distributions, differences in distributions were tested
using the Student independent sample t test, and Wilcoxon
rank-sum tests were used where distributions were skewed.
Univariate and multivariable models were prepared using logis-
tic regression analyses to evaluate associations between predic-
tors and SA-NSCLC. Candidate variables (Table 1) were
identified for testing in multivariable models based on them
approaching statistical significance (P < .15) in univariate mod-
els, having effect estimates clearly apart from the null, or by
knowledge of their role in lung carcinogenesis. Potential nonlin-
ear relationships between continuous covariates and the out-
come were evaluated using multivariable fractional polynomial
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regression (14). No nonlinear relationships were identified, and
they are not discussed further in this report. In evaluating inter-
actions, the main effect terms were included along with the in-
teraction term, and statistical significance of the interaction was
evaluated using likelihood ratio tests (LRTs), comparing nested
models including and excluding the interaction term. Type I (a)
error was set at .05 for main effects and .10 for interaction terms,
and reported P values are two-sided. Significance levels for inter-
action terms were loosened to compensate for reduced cell
counts. Predictor variable inclusion in final multivariable models
was restricted to those for which data were present for more
than 95% of SA-NSCLCs, and where missing data did not differ
significantly by case–control status. To evaluate the likelihood
of overfitting models, the final model was internally validated
using 1000 bootstrap replicates (15). Stata 14.2 software (Stata-
Corp., College Station, TX) was used to conduct analyses.
Results
The NLST had 1458 NSCLCs, and 1338 of these had tumor sizes
available from pathology or clinical data and were eligible for
this study. Cases of SCLC (n¼ 286), carcinoid tumors (n¼ 9), un-
classified tumors (n¼ 279), and other/missing (n¼ 26) were ex-
cluded. There were 64 SA-NSCLCs (4.8% of NSCLCs with size
available), and 206 controls (large, less aggressive NSCLCs,
15.4%). Twenty-three of 195 SCLCs with size measurements
(11.8%) were small aggressive lung cancers (T1, N3, and/or M1),
compared with only 4.8% of NSCLCs (P < .001 for difference in
proportions). Figure 1 describes the case–case selection process
used in this study. Tumor-node-metastasis (TNM) distributions
for the full and adenocarcinoma samples are described in
Table 2. Most SA-NSCLCs were metastatic (M1/stage IV; 84.4%),
with 15.6% of SA-NSCLCs diagnosed as nonmetastatic tumors
with distant nodal spread (T1N3M0/stage IIIB). Most controls
had T2N0M0/stage IB tumors (52.9%). Of 1338 eligible NSCLCs,
906 were primary tumors 30 mm or shorter in the long axis.
Approximately 7.1% (64 of 906) of these were SA-NSCLCs. SA-
NSCLCs ranged from 8 mm to 30 mm (median¼ 18.5 mm, inter-
quartile range [IQR] ¼ 14.0–24.5 mm) in the long axis, with few
(n¼ 3) smaller than 10 mm and the smallest being 8 mm. The le-
sion size for the smallest primary tumor that was metastatic
was 9 mm. The majority (95.3%) of SA-NSCLCs were at or be-
yond 10 mm. Most SA-NSCLCs (71.8%), and all SA-NSCLCs
smaller than 10 mm (n¼ 3), were detected by CXR. Of the 64 SA-
NSCLCs, 14 (21.9%) were diagnosed less than one year after
study entry (T0), and 50 (78.1%) were diagnosed one to seven
years after study entry (T1þ), while among the 206 controls, 61
(29.6%) were T0 and 145 (70.4%) were T1þ diagnoses, respec-
tively (P ¼ .265). In total, 51.9% of cases and 45.3% of controls
were detected during the screening phase of the study, and the
difference was not significant (P ¼ .392).
Table 1. Variables evaluated for associations with SA-NSCLC*
Category of variable Specific variables
Sociodemographics
(n¼5)
Age at diagnosis
Sex
Race/ethnicity
Marital status
Education
Smoking exposures
(n¼5)
Smoking status (former, current)
Pack-years smoked
Smoking duration, (y)
Smoking intensity (average number of
cigarettes smoked/d)
Pipe/cigar smoking
Medical history
(n¼19)
Family history of lung cancer, personal
history of cancer, body mass index
Comorbidities: adult asthma, asbestosis,
bronchiectasis, childhood asthma,
chronic bronchitis, COPD, diabetes,
emphysema, heart attack/heart disease,
hypertension, pneumonia, pulmonary
fibrosis, sarcoidosis, silicosis, stroke, and
tuberculosis
Interaction terms
(n¼6)
Age*sex, age*FHLC, sex*FHLC,
FHLC*smoking duration, FHLC*smoking
intensity, sex*emphysema
*COPD ¼ chronic obstructive pulmonary disease; FHLC ¼ family history of lung
cancer; n ¼ subset number.
National lung screening trial
(n = 53 452)
Excluded:
SCLC/other
(n = 600)
NSCLC
(n = 1 458)
Case +
T1, N3, and/or M1
(n = 64)
Adenocarcinoma
Case -
T2 or T3, N0 to N2, M0
(n = 206)
Case +
(n = 51)
Lung cancers
(n = 2 058)
Case -
(n = 93)
Figure 1. Flow chart depicting the sample selection for cases (small aggressive
non–small cell lung cancers [SA-NSCLC] or caseþ) and controls (larger less-
aggressive NSLSC or case) from the National Lung Screening Trial cohort.
Table 2. TNM stage distribution in SA-NSCLC (light gray) and large
non-SA-NSCLC (dark gray) for NSCLC and adenocarcinoma*
NX No. (%) N0 No. (%) N1 No. (%) N2 No. (%) N3 No. (%)
NSCLC
M0 T1 10 (15.6)
T2 109 (52.9) 31 (15.0) 42 (20.4)
T3 13 (6.3) 1 (0.5) 10 (4.9)
M1 T1 1 (1.6) 12 (18.8) 6 (9.4) 20 (31.3) 15 (23.4)
Adenocarcinoma
M0 T1 9 (17.6)
T2 56 (60.2) 9 (9.7) 21 (22.6)
T3 4 (4.3) 0 (0.0) 3 (3.2)
M1 T1 1 (2.0) 9 (17.6) 4 (7.8) 15 (29.4) 13 (25.5)
*Percentages represent proportions among cases and controls separately.
NSCLC ¼ non–small cell lung cancer; SA-NSCLC ¼ small aggressive non–small
cell lung cancer; TNM ¼ tumor-node-metastasis staging.
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Demographic and clinical characteristics were generally simi-
lar between cases and controls (Table 3). Notable differences in
distributions between cases and controls were found for histol-
ogy, random assignment group (screening arm), and history of
emphysema. Smoking covariates (status, intensity, duration, and
pack-years) were similar between groups. Most SA-NSCLCs
occurred in males (60.9%), though this proportion was lower than
for larger, less aggressive NSCLCs (71.4%). SA-NSCLCs had a sta-
tistically significant univariate association with adenocarcino-
mas, which included bronchioloalveolar carcinomas (OR¼ 4.77,
95% CI¼ 2.44 to 9.30), compared with other NSCLCs (squamous
cell carcinomas, large cell carcinomas, and other combined). This
Table 3. Demographic and clinical characteristics of cases and controls (n¼ 270)*
Variable Case (n¼ 206, 76%) Caseþ (n¼ 64, 24%) P† OR (95% CI)‡
Sociodemographic
Age at diagnosis, mean (SD), y 66.8 (5.8) 66.2 (4.9) .412 0.98 (0.93 to 1.03)
Sex, No. (%)
Male 147 (71.4) 39 (60.9)
Female 59 (28.6) 25 (39.1) .124 1.60 (0.89 to 2.87)
Race/ethnicity, No. (%)
Nonwhite 20 (9.7) 2 (3.1)
White 186 (90.3) 62 (96.9) .118 3.33 (0.76 to 14.7)
Education level, No. (%)
High school or less 79 (38.4) 23 (36.5)
More than high school 127 (62.6) 40 (63.5) .882 1.08 (0.60 to 1.94)
Medical history
Body mass index, mean (SD), kg/m2 27.2 (4.3) 26.6 (3.6) .312 0.96 (0.90 to 1.04)
Family history of lung cancer, No. (%)
No 146 (71.6) 43 (68.2)
Yes 58 (28.4) 20 (31.8) .636 1.17 (0.64 to 2.16)
Sex*FHLC interaction, No. (%)
Male, no FHLC 103 (50.5) 29 (46.0)
Male, FHLC 43 (21.1) 9 (14.3)
Female, no FHLC 43 (21.1) 14 (22.2)
Female, FHLC 15 (7.4) 11 (17.5) .109 3.03 (0.84 to 10.97)
Emphysema§, No. (%)
No 184 (89.3) 50 (79.4)
Yes 22 (10.7) 13 (20.6) .053 2.17 (1.02 to 4.62)
COPD§, No. (%)
No 156 (75.7) 47 (73.4)
Yes 50 (24.3) 17 (26.6) .741 1.13 (0.60 to 2.14)
Chronic bronchitis§, No. (%)
No 182 (8.4) 56 (88.9)
Yes 24 (11.6) 7 (11.1) 1.000 0.95 (0.39 to 2.32)
Exposures
Cigarettes/d, mean (SD) 30.6 (12.7) 31.8 (13.5) .906 1.00 (0.98 to 1.02)
Years smoked, mean (SD) 44.7 (7.1) 44.5 (7.2) .862 1.00 (0.96 to 1.04)
Pack-years, mean (SD) 68.4 (31.4) 68.2 (29.0) .971 1.00 (0.99 to 1.01)
Smoking status, No. (%)
Former 125 (60.7) 40 (62.5)
Current 81 (39.3) 24 (37.5) .884 1.08 (0.61 to 1.93)
Cancer-related
Tumor size, mean (SD), mm 48.2 (15.9) 19.0 (6.1) – –
Histology, No. (%)
Adenocarcinoma 88 (42.7) 49 (76.6) <.001 4.77 (2.44 to 9.30)k
Bronchioloalveolar carcinoma 5 (2.4) 2 (3.1)
Squamous cell carcinoma 95 (46.1) 9 (14.1)
Large cell carcinoma 13 (6.3) 2 (3.1)
Other NSCLCs 5 (2.4) 2 (3.1)
Screening-related
Randomization group, No. (%)
LDCT 90 (43.7) 18 (28.1) .029 0.50 (0.27 to 0.93)
CXR 116 (56.3) 46 (71.9)
*Odds ratios and 95% confidence intervals are from univariate logistic regression analyses. CI ¼ confidence interval; COPD ¼ chronic obstructive pulmonary disease; CXR ¼
chest x-ray; FHLC¼ family history of lung cancer; LC¼ lung cancer; LDCT ¼ low-dose computed tomography; NSCLC ¼ non–small cell lung cancer; OR¼ odds ratio.
†Wilcoxon rank-sum test was used for age, cigarettes per day, years smoked, pack-years, tumor size; Student t test was used for body mass index; Fisher exact test was
used for all categorical covariates.
‡Odds ratios for categorical covariates are aligned in the table with the level of interest.
§Lung comorbidities, such as COPD, chronic bronchitis, and emphysema, were determined through self-report.
kIn the logistic regression odds ratio estimation, adenocarcinomas (including bronchioloalveolar carcinomas) were compared with all other NSCLCs combined.
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finding, along with research that previously identified an associ-
ation of SA-NSCLCs with adenocarcinomas (1), led to subset
analyses of adenocarcinomas in order to identify possible histol-
ogy-specific associations. Adenocarcinoma cases and controls
were similar to the full sample for demographics and clinical
characteristics (Table 4). In univariate analyses, self-reported
history of emphysema (OR¼ 5.56, 95% CI¼ 1.83 to 16.87) and
female sex-positive family history of lung cancer interaction
(OR¼ 3.83, 95% CI¼ 1.02 to 15.78) were statistically significantly
associated with SA-NSCLC.
A final multivariable logistic regression model for adenocar-
cinomas, along with bootstrap bias–corrected estimates, is
presented in Table 5. Sex and family history of lung cancer had a
statistically significant multiplicative interactive association
with SA-NSCLC (bias-corrected ORinteraction ¼ 6.55, 95% CI¼ 1.06
to 50.80). The interaction term statistically significantly improved
the full adenocarcinoma model, when compared with the nested
model without the term (LRT: P ¼ .018). The odds ratios excluding
the interaction term for female sex (OR¼ 1.44) and positive fam-
ily history of lung cancer (OR¼ 1.45) indicate that the expected
multiplicative combination of odds ratio for females with a fam-
ily history of lung cancer is 2.09 (joint effect ¼ 1.44*1.45 ¼ 2.09). In
those with adenocarcinomas, this study identified statistically
significant positive multiplicative interaction for females with a
Table 4. Demographic and clinical characteristics of cases and controls among those with adenocarcinoma (n¼ 144)*
Variable Case n¼93 (65%) Caseþ n¼ 51 (35%) P† OR (95% CI)‡
Sociodemographic
Age at diagnosis, mean (SD), y 66.9 (5.5) 66.6 (5.1) .760 0.99 (0.93 to 1.06)
Sex, No. (%)
Male 63 (67.7) 31 (60.8)
Female 30 (32.3) 20 (39.2) .456 1.35 (0.67 to 2.76)
Race/ethnicity, No. (%)
Nonwhite 6 (6.4) 2 (3.9)
White 87 (93.6) 49 (96.1) .712 1.70 (0.33 to 8.69)
Education level, No. (%)
High school or less 29 (31.2) 18 (36.0)
More than high school 64 (69.8) 32 (64.0) .580 0.81 (0.39 to 1.66)
Medical history
Body mass index, mean (SD), kg/m2 27.5 (4.3) 26.2 (3.3) .064 0.92 (0.83 to 1.01)
Family history of lung cancer, No. (%)
No 68 (73.9) 33 (66.0)
Yes 24 (26.1) 17 (34.0) .338 1.46 (0.69 to 3.08)
Sex*FHLC interaction, No. (%)
Male, no FHLC 44 (47.8) 23 (46.0)
Male, FHLC 19 (20.6) 7 (14.0)
Female, no FHLC 24 (26.1) 10 (20.0)
Female, FHLC 5 (5.4) 10 (20.0) .061 3.83 (1.02 to 15.78)
Emphysema§, No. (%)
No 88 (94.6) 38 (76.0)
Yes 5 (5.4) 12 (24.0) .002 5.56 (1.83 to 16.87)
COPD§, No. (%)
No 73 (78.5) 36 (70.6)
Yes 20 (22.5) 15 (29.4) .314 1.52 (0.70 to 3.32)
Chronic bronchitis§, No. (%)
No 79 (85.0) 43 (86.0)
Yes 14 (15.0) 7 (14.0) 1.000 0.92 (0.34 to 2.45)
Exposures
Cigarettes/d, mean (SD) 31.1 (13.5) 30.9 (14.0) .915 1.00 (0.97 to 1.02)
Years smoked, mean (SD) 43.7 (6.7) 45.3 (7.3) .202 1.03 (0.98 to 1.09)
Pack-years, mean (SD) 68.1 (33.6) 69.0 (29.3) .873 1.00 (0.99 to 1.01)
Smoking status, No. (%)
Former 44 (47.3) 19 (37.2)
Current 49 (52.7) 32 (63.8) .293 1.51 (0.75 to 3.04)
Cancer-related
Tumor size, mean (SD), mm 45.8 (14.5) 18.9 (6.2) – –
Screening-related
Randomization group, No. (%)
LDCT 39 (41.9) 16 (31.4)
CXR 54 (58.1) 35 (68.6) .282 0.63 (0.31 to 1.30)
*Odds ratios and 95% confidence intervals are from univariate logistic regression analyses. CI ¼ confidence interval; COPD ¼ chronic obstructive pulmonary disease;
CXR ¼ chest x-ray; FHLC ¼ family history of lung cancer; LC ¼ lung cancer; LDCT ¼ low-dose computed tomography; OR ¼ odds ratio.
†Wilcoxon rank-sum test was used for age, cigarettes per day, years smoked, pack-years, tumor size; Student t test was used for body mass index; and Fisher exact test
was used for all categorical covariates.
‡Odds ratios for categorical covariates are aligned in the table with the level of interest.
§Lung comorbidities, such as COPD, chronic bronchitis, and emphysema, were determined through self-report.
M. T. Warkentin et al. | 5 of 8
family history of lung cancer compared with males without, with
an adjusted odds ratio for the joint effect of 3.62 (95% CI¼ 1.06 to
12.34). We further evaluated this interaction among SCLC, and
the associations did not approach statistical significance
(Pinteraction ¼ .68). Due to small numbers of SCLC cases (n¼ 23)
and controls (n¼ 20) and wide confidence intervals, these find-
ings should be interpreted cautiously.
The previously reported association of SA-NSCLC with youn-
ger age at diagnosis was not observed in the current study, and
the association with ibuprofen use could not be validated as
ibuprofen use was not measured in NLST (1). Age at diagnosis
showed a suggestive inverse trend with SA-NSCLC risk, but these
effects were attenuated when models were adjusted for sex
and histology, as adenocarcinomas and females were both asso-
ciated with younger age at diagnosis (data not shown).
Associations for screening arm with sex or family history of lung
cancer were not observed (data not shown), suggesting that con-
founding by trial arm is unlikely. Exploratory analyses identified
an association between SA-NSCLC and emphysema in the final
multivariable model (OR¼ 5.15, 95% CI¼ 1.63 to 23.00).
Discussion
Females with a family history of lung cancer in a first-degree rel-
ative are at statistically significantly increased risk of having
small aggressive lung adenocarcinomas. This result validates
findings from a previous study in a separate population (1) and
provides a basis for future research on the role of female hor-
mones in lung carcinogenesis and clinical progression, partic-
ularly in those with a family history of lung cancer. Further
research is needed to elucidate the genetic, epigenetic, and envi-
ronmental mechanisms contributing to increased familial risk.
A history of emphysema may also lead to early disease progres-
sion and metastases indicative of relevant tobacco-related lung
damage. All participants were heavy current or former smokers,
so the comparisons of other potential risk factors were all done
in a population with a history of tobacco exposure.
The primary control group used to address the study objec-
tives included patients with tumors that were T2 to T3, N0 to
N2, and M0. Less aggressive T1 tumors were excluded from the
control group to avoid potential misclassification, as these
tumors still have the potential to spread to distant lymph
nodes and metastasize, and thus could be early SA-NSCLC.
Similarly, large aggressive tumors (>30 mm, T4/N3/M1) were
excluded as they could have been SA-NSCLCs that had the
opportunity for the primary tumor to grow in size and were
identified later in disease course. As such, the control group
only contains tumors that have not gone through the SA-NSCLC
disease course.
Although the NLST participants were more white, more edu-
cated, and more likely to be former smokers than the general
US population (16,17), in large part, the findings of the current
study reflect biological processes and are expected to be gener-
alizable beyond the NLST cohort. Computed tomography imag-
ing can detect smaller lung nodules than CXR (18), but in this
study more SA-NSCLCs were detected by CXR. Random sam-
pling variation may account for this difference.
Despite evidence suggesting that adenocarcinomas are more
likely to have early metastases (19,20), including a recent study
that identified an adenocarcinoma subtype with an aggressive
phenotype in early stage (21), they generally have been shown
to have similar or slightly better prognosis than other histolo-
gies (20,22,23). Our previous study found a similar association of
SA-NSCLCs with adenocarcinomas when compared with other
NSCLC histologies (1). Adenocarcinomas are disproportionately
higher in females than males, despite being the most common
lung cancer subtype for both sexes (20,24,25). In this study, SA-
NSCLCs were found to be significantly associated with adeno-
carcinomas. The sex–family history interaction persisted within
adenocarcinoma, suggesting that this finding is not confounded
by early metastases being more common in adenocarcinomas,
which are more common in women, those with a family history
of lung cancer, and younger individuals (24–26).
The link between female factors, such as sex hormones, and
heritable genetic variations in causing lung cancer is not clear,
but there is cause for speculation. Compared with somatic gene
mutations, less is known of inherited gene mutations in the de-
velopment of lung cancer. KRAS gene mutations are the most
frequently occurring mutated oncogenes in lung adenocarcino-
mas (27). A germline single nucleotide polymorphism
(rs61764370) in the 3’-untranslated region of the KRAS onco-
gene, termed the KRAS variant, has been identified as an inher-
ited mutation that may play a role in cancer risk and altered
tumor biology (28). Carriers of this gene variant tend to develop
highly aggressive cancers (28,29). A relationship between hor-
monal exposure and breast cancer risk in women with the
KRAS variant has been observed, and it suggests a possible in-
teraction between this variant and female sex hormones for in-
creasing breast cancer risk, and may predict aggressive tumor
biology (28,29). A similar relationship may exist in lung cancer.
No association was observed for overall familial or sporadic
breast cancer risk and the variant (28). Results from two case–
control studies identified 1.4- and 2.3-fold increases in the risk
of NSCLC for below-median smokers (<40 and <41 pack-years,
respectively) with the KRAS risk allele, but no overall
association among heavier smokers (30). A meta-analysis found
no association between the KRAS variant (rs61764370) and
overall risk of ovarian, breast, or colorectal cancer (31). These
pooled findings did not account for potential interaction with
hormonal exposures. Future molecular epidemiologic studies
may investigate germline genetic variants associated with a
family history of SA-NSCLC and how these variants interact
with the female hormone environment. Existing tissue microar-
rays and DNA cores assembled for the PLCO and NLST could be
used for these and other similar purposes.
In univariate and multivariable analyses, SA-NSCLCs were
associated with history of emphysema. Lung comorbidities
have been linked to an increased risk of developing lung cancer
Table 5. Final and bootstrap bias–corrected multivariable logistic re-
gression estimates of associations with SA-NSCLC among individu-
als with adenocarcinomas (n¼ 142)*
Final model Bias-corrected model
Variable OR (95% CI), P OR (95% CI), P
Emphysema
diagnosis
(yes vs no)
5.85 (1.82 to 18.82), .003 5.15 (1.63 to 23.00), .007
Sex (female
vs male)
0.86 (0.34 to 2.16), .752 0.88 (0.35 to 2.21), .763
FHLC (yes vs no) 0.56 (0.19 to 1.65), .296 0.59 (0.11 to 1.59), .359
Sex*FHLC
interaction
7.47 (1.34 to 41.71), .022 6.55 (1.06 to 50.80), .042
*CI ¼ confidence interval; FHLC ¼ family history of lung cancer; OR ¼ odds ratio;
SA-NSCLC ¼ small aggressive non–small cell lung cancer.
6 of 8 | JNCI J Natl Cancer Inst, 2018, Vol. 2, No. 1
(32); however, the current study implicates lung disease as play-
ing a role in early lung cancer progression. Chronic obstructive
pulmonary diseases, such as emphysema, are pathologically
characterized by activation of inflammatory processes of the
lung (33–36). The proposed mechanisms by which an inflamma-
tory response could contribute to carcinogenesis include in-
creased genetic mutations, anti-apoptotic signaling, and
increased angiogenesis (32). Increased angiogenesis is consid-
ered a required precursor for tumor growth, and for tumor cells
to enter the blood stream and metastasize (37,38). Avascular
tumors have limited capacity for growth and metastases (37).
Inflammation can activate cell populations that release angio-
genic factors (39). Increased levels of proangiogenic factors may
allow for increased vascularization of tumors, increasing
growth and metastatic potential (37,38). Lung comorbidity, in
particular emphysema, is an important factor to consider in a
population with extensive history of tobacco use.
The metastatic potential of NSCLC has been consistently
linked with tumor size (2,3,40–43). This is likely because the fac-
tors that promote tumor growth also increase metastatic poten-
tial (39). Little is known about possible lower boundaries of size
for a tumor to develop a profile necessary to become metastatic
or locally invasive. Research has suggested that the angiogene-
sis required for a solid tumor to become metastatic occurs by
the time a tumor is 1 to 2 mm (42). Nodules as small as 1 mm
were detected in the NLST, though no NSCLCs were this small.
The frequency of metastases increased substantially at or be-
yond 10 mm tumor sizes, and for those lung tumors that met
the criteria of being SA-NSCLC, the smallest was 8 mm. Ten mm
may represent an approximate lower bound for SA-NSCLC de-
velopment. Lung tumors 3 cm or smaller in size, with limited in-
vasion of surrounding tissue (T1), are further subclassified as
T1a if the tumor is 2 cm or smaller in the long axis (TNM–AJCC,
7th ed.) (44). If 10 mm is an approximate lower boundary for
tumors to become regionally aggressive and/or metastasize, fu-
ture studies may consider revising the T1 subclassification to
better reflect tumor biology.
A limitation of the current study is its small sample size,
which was a consequence of the case–case study design. The
conclusions drawn from this study may need to be replicated
with a larger sample size. On the other hand, the nested case–
case study took place in a large, semirepresentative, defined co-
hort, with carefully measured outcome and predictor variables.
Recall bias was eliminated by prospective data collection, and
selection biases were minimized by sampling all eligible cases
and controls from within the same cohort.
In summary, this study validates the finding that in a popu-
lation with an extensive smoking history, women with a family
history of lung cancer are at elevated risk of small aggressive
lung adenocarcinomas, suggesting that heritable factors may
interact with sex-specific factors in the early progression of
adenocarcinomas. In addition, SA-NSCLC is associated with a
history of emphysema. Knowledge of the gene-sex interaction
and biology of SA-NSCLC might lead to a better understanding
of carcinogenesis and cancer progression, as well as identifica-
tion of high-risk populations that might benefit from screening
or increased clinical monitoring, and may lead to effective che-
moprevention and improved therapeutics.
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